Clinical Trials Logo
  1. Home
  2. Age-Related Macular Degeneration
  3. NCT01255774

Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy — FVF4193s  

Age Related Macular Degeneration Clinical Trial

Official title:
Serial Retinal Thickness Changes And Scotoma Size Measured With Lucentis Therapy Measured Using The Optical Coherence Tomography (OCT) Scanning Laser Ophthalmoscope (SLO) And The Foresee Preferential Hyperacuity Perimeter

Clinical Trial Summary

The rationale for evaluating LucentisTM (a recombinant humanized anti-human Vascular Endothelial Growth Factor (VEGF) monoclonal antibody (Fab) in patients with neovascular (wet) Age related Macular Degeneration (AMD) is based on the strong correlation between VEGF levels in aqueous and vitreous humor and active blood vessel formation. LucentisTM has been shown to maintain or improve vision in wet AMD. Since the treatments do not halt the loss of visual acuity in wet AMD, it is important to accurately measure anatomic response to treatments thereby enhancing the ability to understand patterns of response and predict the necessity for continued therapy.

Clinical Trial Description

n/a

Study Design

Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT01255774
Study type Interventional
Source The New York Eye & Ear Infirmary
Contact Katy W Tai, CCRC
Phone 212-979-4251
Email ktai@nyee.edu
Status Recruiting
Phase Phase 3
Start date June 2007
Completion date December 2012
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT03963817 - Snapshot Camera for AMD
Recruiting NCT04929756 - Eye Movement Rehabilitation in Low Vision Patients
Completed NCT04779398 - Association of MPOD Values With Blue Light.
Terminated NCT03275753 - Visual Function Tests in Age-related Macular Degeneration
Recruiting NCT03609307 - Comparison of Treatment Response to Intravitreal Injection of Combined Propranolol and Bevacizumab Versus Bevacizumab Monotherapy in Patients With Wet Age Related Macular Degeneration :A Clinical Trial Phase 2/Phase 3
Completed NCT02909985 - Visual Activity Evoked by Infrared in Humans After Dark Adaptation N/A
Completed NCT02556723 - Intravitreal Injections of Ziv-aflibercept for Macular Diseases N/A
Active, not recruiting NCT01943396 - Treatment of AMD With Rheohemapheresis /RHF/ Phase 4
Completed NCT00963339 - Age-Related Macular Degeneration (AMD) - Usability Study N/A
Completed NCT00376701 - Combination Therapy for Age-Related Macular Degeneration. Phase 2
Completed NCT00800995 - Superoxide Dismutase (SOD) as Antioxidant Treatment OF Age Related Macular Degeneration (ARMD) Phase 3
Terminated NCT00347165 - Intravitreal Bevacizumab for Age-Related Macular Degeneration Phase 2
Completed NCT04689789 - OCTA and Retinal Angiomatous Proliferation
Completed NCT02567604 - Development of Core Outcomes for Age-related Macular Degeneration (AMD) Interventions- Caregivers' Perspective
Completed NCT02173496 - Colour Contrast Sensitivity for the Early Detection of Wet Age-related Macular Degereration (CEDAR)
Recruiting NCT01991730 - Observational Study to Evaluate and Compare the Rate and Extent of Inflammation After a Single Injection of Ranibizumab vs. a Single Intravitreal Injection of Aflibercept in Treatment Naive and Treatment Experienced Patients N/A
Active, not recruiting NCT01657669 - Short-term Clinical Effects of Intravitreal Aflibercept Injection 2.0mg as a Predictor of Long-term Results Phase 4
Completed NCT00776763 - Ocular Growth Factors Profile in Proliferative Retinopathies Before and After Intravitreal Bevacizumab Phase 2
Completed NCT00791570 - Anti-VEGFR Vaccine Therapy in Treating Patients With Neovascular Maculopathy Phase 1
Completed NCT00413829 - Immediate Effects of Lucentis® in Conjunction With Photodynamic Therapy With Visudyne® in Exudative AMD(IECOMB) Phase 2